New and Repurposed Drugs for the Treatment of Active Tuberculosis : An Update for Clinicians
© 2022 The Author(s). Published by S. Karger AG, Basel..
Although tuberculosis (TB) is preventable and curable, the lengthy treatment (generally 6 months), poor patient adherence, high inter-individual variability in pharmacokinetics (PK), emergence of drug resistance, presence of comorbidities, and adverse drug reactions complicate TB therapy and drive the need for new drugs and/or regimens. Hence, new compounds are being developed, available drugs are repurposed, and the dosing of existing drugs is optimized, resulting in the largest drug development portfolio in TB history. This review highlights a selection of clinically available drug candidates that could be part of future TB regimens, including bedaquiline, delamanid, pretomanid, linezolid, clofazimine, optimized (high dose) rifampicin, rifapentine, and para-aminosalicylic acid. The review covers drug development history, preclinical data, PK, and current clinical development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:102 |
|---|---|
| Enthalten in: |
Respiration; international review of thoracic diseases - 102(2023), 2 vom: 13., Seite 83-100 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aguilar Diaz, Jessica M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antitubercular Agents |
|---|
| Anmerkungen: |
Date Completed 07.02.2023 Date Revised 03.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000528274 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350287678 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350287678 | ||
| 003 | DE-627 | ||
| 005 | 20231226044648.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000528274 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM350287678 | ||
| 035 | |a (NLM)36516792 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aguilar Diaz, Jessica M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New and Repurposed Drugs for the Treatment of Active Tuberculosis |b An Update for Clinicians |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.02.2023 | ||
| 500 | |a Date Revised 03.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Author(s). Published by S. Karger AG, Basel. | ||
| 520 | |a Although tuberculosis (TB) is preventable and curable, the lengthy treatment (generally 6 months), poor patient adherence, high inter-individual variability in pharmacokinetics (PK), emergence of drug resistance, presence of comorbidities, and adverse drug reactions complicate TB therapy and drive the need for new drugs and/or regimens. Hence, new compounds are being developed, available drugs are repurposed, and the dosing of existing drugs is optimized, resulting in the largest drug development portfolio in TB history. This review highlights a selection of clinically available drug candidates that could be part of future TB regimens, including bedaquiline, delamanid, pretomanid, linezolid, clofazimine, optimized (high dose) rifampicin, rifapentine, and para-aminosalicylic acid. The review covers drug development history, preclinical data, PK, and current clinical development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Drugs | |
| 650 | 4 | |a Treatment | |
| 650 | 4 | |a Tuberculosis | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 650 | 7 | |a Linezolid |2 NLM | |
| 650 | 7 | |a ISQ9I6J12J |2 NLM | |
| 700 | 1 | |a Abulfathi, Ahmed A |e verfasserin |4 aut | |
| 700 | 1 | |a Te Brake, Lindsey Hm |e verfasserin |4 aut | |
| 700 | 1 | |a van Ingen, Jakko |e verfasserin |4 aut | |
| 700 | 1 | |a Kuipers, Saskia |e verfasserin |4 aut | |
| 700 | 1 | |a Magis-Escurra, Cecile |e verfasserin |4 aut | |
| 700 | 1 | |a Raaijmakers, Jelmer |e verfasserin |4 aut | |
| 700 | 1 | |a Svensson, Elin M |e verfasserin |4 aut | |
| 700 | 1 | |a Boeree, Martin J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiration; international review of thoracic diseases |d 1968 |g 102(2023), 2 vom: 13., Seite 83-100 |w (DE-627)NLM000076384 |x 1423-0356 |7 nnns |
| 773 | 1 | 8 | |g volume:102 |g year:2023 |g number:2 |g day:13 |g pages:83-100 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000528274 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 102 |j 2023 |e 2 |b 13 |h 83-100 | ||